Document:

Exhibit

EXHIBIT 10.1

AMENDMENT NO. 4 TO 
SYNNEX CORPORATION 
2013 STOCK INCENTIVE PLAN

In accordance with Section 18(b) of the SYNNEX Corporation 2013 Stock Incentive Plan (the “Plan”), the Plan is hereby amended as follows, effective as of March 21, 2017.
1.    Section 4(b) (ii) is hereby amended in its entirety as follows.
(ii)    On the first trading day following the conclusion of each regular annual meeting of the Company's stockholders after such Outside Director's appointment or election to the Board of Directors, commencing with the first annual meeting occurring on or after January 4, 2017, each Outside Director who will continue serving as a member of the Board of Directors thereafter shall receive a number of whole Restricted Shares equal to $125,000 divided by the Fair Market Value of a Share as of such grant date, provided if the first trading day following the conclusion of the regular annual meeting of the Company's stockholders after such Outside Director's appointment or election to the Board of Directors falls within a trading black-out period, then the grant date for Restricted Shares granted pursuant to this Section 4(b) (ii) shall be upon the expiration of the third trading day after the trading black-out period ends. For purposes of the calculation in the preceding sentence, any fractional Restricted Shares shall be disregarded.
To record the amendment of the Plan, SYNNEX Corporation has executed this document this day of March 28, 2017.

SYNNEX CORPORATION
By:_/s/ Simon Leung                    
Title: Senior Vice President, General Counsel and Corporate Secretary

1Exhibit 10.1

 

Exhibit No. 10.1 Form of Securities Purchase
Agreement

 

BioHiTech Global, Inc.

 

Securities
Purchase Agreement

 

Investor
Package

 

_____________, 2016

 

     

     

    

 

INSTRUCTIONS FOR INVESTING

 

If you wish to purchase the offered securities
of BioHiTech Global, Inc., please:

 

		(1)	Review this Securities Purchase Agreement, Note and Warrant.

 

		(2)	Indicate where appropriate, in Exhibit A for U.S.
residents and Exhibit B for non-U.S. residents, to the Securities Purchase Agreement, your status as an Accredited Investor
by initialing the appropriate accreditation categories.

 

		(3)	Type or print all information required in the blank sections
in Exhibit A or Exhibit B, as applicable, to the Securities Purchase Agreement, including your requested subscription
amount, your federal taxpayer identification number, and your primary residence or, in the case of an entity, your principal place
of business.

 

		(4)	Execute the signature page to the Securities Purchase Agreement.

 

		(5)	Pay for the full amount of your investment by means of
a check made payable to “ BioHiTech Global, Inc.” or a wire transfer to the following:

 

TD Bank, N.A.

2035 Limestone Rd.

Wilmington, DE

SWIFT: _________

ABA: _________

ACCT #: _________

ACCOUNT NAME:. __________-

 

		(6)	Send the completed and executed signature pages to this
Securities Purchase Agreement, the completed Purchaser Questionnaire  (Exhibit A or Exhibit B) to the
Company, preferably by fax or e-mail:

 

BioHiTech Global, Inc.

Attn: Brian C. Essman

80 Red Schoolhouse Rd.

Chestnut Ridge, New York 10977

Fax: ______

Email: _______

 

    The Company may
choose not to accept all or some of any investor’s subscription for any reason (regardless of whether any check or wire transfer
relating to this subscription is deposited in a bank or trust account).  The Company will send to you a fully executed
copy of the transaction documents if your subscription is accepted.  If you have any questions in completing the transaction
documents, please contact Brian C. Essman at (845) ____________.

 

    	i 

     

    

 

BIOHITECH GLOBAL, INC.

SECURITIES PURCHASE AGREEMENT

 

This Securities Purchase Agreement (the
“Agreement”) is entered into by and between BioHiTech Global, Inc., a Delaware corporation (the “Company”),
and the undersigned purchaser or purchasers (the “Purchaser”, and collectively with other purchasers similarly
situated, the “Purchasers”) as of the latest date set forth on the signature page hereto.

 

NOW, THEREFORE, in consideration
of the mutual covenants and other agreements contained in this Agreement, the Company and the Purchaser hereby agree as follows:

 

1.             Purchase
of Securities. 

 

(a)           Subject
to the terms and conditions of this Agreement, the undersigned Purchaser hereby subscribes for units (the “Units”),
each Unit comprised of: (i) an unsecured subordinated convertible promissory note (“Note”), in the form attached
as Exhibit C hereto, in the principal amount of $25,000 and convertible into shares (“Shares”) of the
Company’s common stock, $0.0001 par value (the “Common Stock”), as described below and (ii) a five-year
warrant (“Warrant”), in the form attached as Exhibit D hereto, to purchase such number of shares of Common
Stock equal to the number of Shares issuable upon conversion of the corresponding Note (sometimes the Notes, the Shares and the
Warrant are collectively referred to as the “Securities”). The total amount to be paid for the Securities shall
be the amount accepted by the Company in connection with this investment, which may be less than or equal to the amount indicated
by the undersigned Purchaser on the signature page hereto (the “Subscription Amount”).  The offering,
purchase and sale of the Securities is referred to herein as the “Offering.”

 

(b)           The
Units are being offered by the Company only to persons who qualify as “accredited investors” or “qualified institutional
buyers” as defined in Rule 501 of Regulation D or persons who are not “U.S. persons” as defined in Rule 902(k)
of Regulation S, each as promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The
Company shall sell a minimum of 40 Units (the “Minimum Amount”) and up to a maximum of 300 Units (the “Maximum
Amount”) to the Purchasers, for aggregate gross proceeds to the Company of $1,000,000 to $7,500,000. The minimum Subscription
Amount that any single Purchaser may invest in this Offering is $25,000, provided that the Company may, in its sole discretion
and without notice to the other Purchasers, accept Subscription Amounts for lesser amounts. The Units are being sold on a “best
efforts, all or none” basis with respect to the Minimum Amount and on a “best efforts” basis with respect to
the Maximum Amount. Subscriptions for Units may not be revoked once tendered, except pursuant to law.

 

(c)          The
Note shall accrue interest at a rate of 8% per annum. Subject to one or more Optional Conversions (as defined below), the principal
amount of the Note, as well as all other amounts payable under the Note, including interest, shall be repaid on the earliest of
(x) the date of the Listing (as defined below), (y) the date of the Change of Control (as defined in the Note), and (z) 24 months
after the Initial Closing Date (as defined below). Such time is referred to as “Maturity”. All amounts to be
paid at Maturity, except for interest, shall be paid in shares of the Company’s Common Stock at a per-share conversion price
(the “Conversion Price”) equal to the lowest of: (i) $2.75 (the “Closing Price”), (ii) the
Listing Price (as defined below), (iii) the Public Offering Price (as defined below), (iv) the Private Offering Price (as defined
below), and (v) the Change of Control Price (as defined in the Note).  Interest due at Maturity shall be paid at the Company’s
option in shares, or cash, or a mix of both, with the amount of any such shares being determined at a per-share conversion price
equal to the closing price of the Company’s Common Stock on the U.S. public trading market on which the Common Stock then
trades on the trading day immediately prior to the payment date.  Prior to Maturity, the Note shall be convertible, in whole
or in part, along with a proportional amount of all other amounts then payable under the Note, including interest, at the holder’s
option, at the Closing Price (each such optional conversion, an “Optional Conversion”). All amounts to be paid
upon an Optional Conversion, except for interest, shall be paid in shares of the Company’s Common Stock. Interest to be paid
upon an Optional Conversion shall be paid at the Company’s option in shares, or cash, or a mix of both.

 

As used herein, the “Listing Price”
means the lower of the opening and closing per-share market prices (as appropriately adjusted to reflect stock dividends, stock
splits, combinations, recapitalizations and the like with respect to the Company’s capital stock after the date hereof) on
such day that the Company’s Common Stock is first traded on The Nasdaq Stock Market or NYSE MKT (the “Listing”),
the “Public Offering Price” means the price per share (as appropriately adjusted to reflect stock dividends,
stock splits, combinations, recapitalizations and the like with respect to the Company’s capital stock after the date hereof)
paid by public investors in an underwritten public offering conducted in connection with the Listing, without regard to any underwriting
discount or other offering expense (such an offering, a “Public Offering”), and the “Private Offering
Price” means the lowest price per share (as appropriately adjusted to reflect stock dividends, stock splits, combinations,
recapitalizations and the like with respect to the Company’s capital stock after the date hereof) paid by investors in any
private equity, equity-linked or debt financing (other than this Offering) conducted after the date hereof prior to the Listing,
without regard to any broker’s fee or other offering expense. To the extent there are differences in the terms of the Note
as described herein and as described in the Note, the terms as described in the Note shall prevail.

 

    	 	2	 

     

    

 

(d)           The
Warrant has a five (5) year term expiring on that date that is five (5) years after the issue date (the “Expiration Date”).  The
Warrant shall be exercisable in whole or in part at any time beginning on the date on which the Note issued in connection with
the Offering has been converted into Common Stock and continuing thereafter and from time to time on or prior to the Expiration
Date. The Warrant shall be exercisable for such number of shares of Common Stock equal to the number of Shares issuable upon conversion
of the corresponding Note at a per-share exercise price equal to 120% of the Conversion Price; provided, however, that if the Conversion
Price is ever adjusted pursuant to the terms of the Note (the “Adjusted Conversion Price”), the exercise price
of the Warrant shall be adjusted for any unexercised Warrants such that the exercise price will equal 120% of the Adjusted Conversion
Price. To the extent there are differences in the terms of the Warrant as described herein and as described in the Warrant, the
terms as described in the Warrant shall prevail.

 

(e)           Units
shall be delivered to the Purchaser in the form of separate Notes and Warrants.

 

(f)           The
Company is conducting this Offering without a third party broker or placement agent; however, the Company may engage such a third
party at any time during the pendency of the Offering in its sole discretion pursuant to such terms and conditions as the Company
may deem necessary or appropriate in its sole discretion.

  

2.           Closing.

 

(a)           On
or prior to the applicable Closing Date (as defined below), the Purchaser shall deliver or cause to be delivered to the Company
the following deliverables in accordance with the subscription procedures described in Section 2(b) below:

 

(i)          a
completed and duly executed signature page of this Agreement; and

 

(ii)         the
completed Purchaser Questionnaire included as Exhibit A or Exhibit B, as applicable, attached hereto.

 

(b)          The
Purchaser shall deliver or cause to be delivered, preferably by fax or e-mail, the deliverables described above to the Company
at the following address:

 

BioHiTech Global, Inc.

Attn: Brian C. Essman

80 Red Schoolhouse Rd.

Chestnut Ridge, New York 10977

Fax: _________

Email: ___________

 

Immediately following receipt of the deliverables described
above from all of the Purchasers and acceptance by the Company in accordance with subsection (c) below, payment instructions will
be forwarded to the Purchaser and the Purchaser shall be obligated to deliver funds no later than three business days thereafter.
If the Subscription Amount is to be paid by check, the check must be mailed to the Company at the address above in time to be received
by the deadline described above. If the Subscription Amount is to be paid by wire transfer, it must be wired to the following account
in time to be received by the deadline described above:

 

TD Bank, N.A.

2035 Limestone Rd.

Wilmington, DE

SWIFT: ________

ABA: __________-

ACCT #: _________

ACCOUNT NAME: _______________

 

(c)            This
Agreement sets forth various representations, warranties, covenants, and agreements of the Company and of the Purchaser, as the
case may be, all of which shall be deemed made, and shall be effective without further action by the Company or the Purchaser,
immediately upon the Company’s acceptance of the Purchaser’s subscription and shall thereupon be binding upon the Company
and the Purchaser.  Acceptance shall be evidenced only by execution of this Agreement by the Company on its signature
page attached hereto.  Upon the Company’s acceptance of the Purchaser’s subscription and receipt of the Subscription
Amount, on the applicable Closing Date, the Company shall deliver to the Purchaser a duly executed copy of each of the Agreement,
the Note and the Warrant.

 

    	 	3	 

     

    

 

(d)        Purchases
and sales of the Securities shall be initially consummated on or before November 30, 2016 (the “Initial Closing Date”),
and shall thereafter be additionally consummated in one or more additional closings (each such consummation, if any, a “Subsequent
Closing” occurring on a “Subsequent Closing Date”). All purchases and sales of Units must be consummated
before the earlier to occur of: (i) December 30, 2016 (the “Termination Date”) and (ii) three trading days after
the date on which the Maximum Amount is subscribed for by investors and accepted by the Company (the “Maximum Amount Subscription
Acceptance Date,” and the earlier to occur of the Termination Date and the Maximum Amount Subscription Acceptance Date
being referred to as the “Final Closing Date,” and each of the Initial Closing Date, any Subsequent Closing
Date and the Final Closing Date being referred to as a “Closing Date”), provided that the Termination Date may
be extended by two (2) 45-day periods in the sole discretion of the Company and without notice to the Purchasers. The aggregate
amount of purchases and sales of Securities in the Offering shall not exceed $7,500,000.

 

3.          Company
Representations and Warranties. The Company hereby represents and warrants that, as of each of the date of this Agreement
and the Closing Date applicable to the Purchaser:

 

(a)         Organization
and Business.  The Company is a corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted and as proposed
to be conducted.  The Company is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction
in which its ownership or use of property or the nature of the business conducted by it makes such qualification necessary except
where failure to do so would have a Material Adverse Effect (as defined in Section 3(o) below). Each subsidiary of the Company
listed on Schedule 3(a) hereto (the “Subsidiaries” and each a “Subsidiary”) has been
duly incorporated and is validly existing as a corporation in good standing under the laws of its jurisdiction of incorporation,
with corporate power and authority to own, lease and operate its properties and conduct its business as now conducted and as proposed
to be conducted, and has been duly qualified as a foreign corporation for the transaction of business and is in good standing under
the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification.
As of the date of this Agreement, except for the entities listed on Schedule 3(a) hereto, the Company does not own or control,
directly or indirectly, any equity or other ownership interest in any corporation, partnership, joint venture or any other Person.
 “Person” means an individual, entity, partnership, limited liability company, corporation, association,
trust, joint venture, unincorporated organization, and any government, governmental department or agency or political subdivision
thereof.

 

(b)         Capitalization.

 

(i)          The
Company has two classes of authorized capital stock consisting of 20,000,000 shares of Common Stock and 10,000,000 shares of preferred
stock, par value $0.0001 per share (the “Preferred Stock”) of which 8,229,712 shares of Common Stock are issued
and outstanding and 0 shares of Preferred Stock are issued and outstanding.  Schedule 3(b)(i) includes a summary
of the Company’s capitalization as of the date of this Agreement and as of the applicable Closing Date, and all of such capital
stock of the Company has been duly and validly authorized and issued, fully paid and nonassessable. All of the issued share capital
of each Subsidiary have been duly and validly authorized and issued, and are fully paid in accordance with its articles of incorporation,
articles of association or applicable foreign, federal, state and local laws, including, without limitation, the corporate law
of the jurisdiction of the Company’s incorporation, and are nonassessable, if applicable. All of the issued share capital
or equity interest, as the case may be, of each Subsidiary is owned directly or indirectly by the Company, free and clear of all
Liens, equities or claims. There are no outstanding securities convertible into or exchangeable for, or warrants, rights or options
to purchase from any Subsidiary, no obligation of any Subsidiary to issue, equity shares or any other class of share capital of
any Subsidiary.

 

(ii)         Except
as set forth on Schedule 3(b)(ii) to this Agreement: (A) there are no outstanding options, warrants, scrip, rights to subscribe
for, puts, calls, rights of first refusal, agreements, understandings, claims or other commitments or rights of any character whatsoever
relating to, or securities or rights convertible into or exchangeable for, any capital stock of the Company, or arrangements by
which the Company is or may become bound to issue additional capital stock, (B) there are no agreements or arrangements under which
the Company is obligated to register the sale of any of its or their securities under the Securities Act and (C) there are no anti-dilution
or price adjustment provisions contained in any security issued by the Company (or in any agreement providing rights to security
holders) that will be triggered by the issuance of the Securities.

 

(iii)        No
shares of capital stock of the Company are subject to preemptive rights or any other similar rights of anyone or any mortgage,
lien, title claim, assignment, encumbrance, security interest, adverse claim, contract of sale, restriction on use or transfer
(other than restrictions on transfer under applicable state and federal securities laws or “blue sky” or other similar
laws (collectively, the “Securities Laws”)) or other defect of title of any kind (each, a “Lien”)
imposed through the actions or failure to act of the Company. No further approval or authorization of any shareholder, the Board
of Directors or others is required for the issuance and sale of the Securities.

 

    	 	4	 

     

    

 

(iv)        Except
as set forth on Schedule 3(b)(iv), no Subsidiary of the Company is currently prohibited, directly or indirectly, under any
agreement or other instrument to which it is a party or is subject, from paying any dividends to its shareholders, from making
any other distribution on such subsidiary’s issued share capital, from repaying to the Company or any other Subsidiary of
the Company any loans or advances to such subsidiary from the Company or such other Subsidiary or from transferring any of such
Subsidiary’s properties or assets to any of the Company or other Subsidiary.

 

(c)          Authorization;
Enforceability.  All corporate action on the part of the Company, its officers, directors and shareholders necessary
for the authorization, execution and delivery of the Transaction Documents (as defined in subsection (f) below), the performance
of all obligations of the Company under the Transaction Documents, and the authorization, issuance, sale and delivery of the Securities
has been taken, and each Transaction Document constitutes a legal, valid and binding obligation of the Company, enforceable against
the Company in accordance with its terms, except to the extent limited by applicable bankruptcy, insolvency, reorganization, moratorium
or other laws of general application affecting enforcement of creditors’ rights and general principles of equity that restrict
the availability of equitable or legal remedies.

 

(d)          Valid
Issuance.  The Securities being acquired by the Purchaser hereunder, are duly authorized for issuance and sale to
the Purchaser, and, when issued, sold and delivered in accordance with the terms of this Agreement for the consideration, will
be validly issued, fully paid, and non-assessable, and free from all Liens. The shares of Common Stock to be issued pursuant to
the exercise of the Warrants or conversion of the Notes are duly authorized and reserved for issuance and, upon exercise of the
Warrants or conversion of the Notes in accordance with its terms, will be validly issued, fully paid and non-assessable and free
from all Liens.

 

(e)          Litigation. 
There is no material action, suit, proceeding or investigation pending or, to the Company’s knowledge, currently threatened
against the Company.  The Company is not a party or subject to the provisions of any order, writ, injunction, judgment
or decree of any court or government agency or instrumentality.  There is no action, suit, proceeding or investigation
by the Company currently pending or that the Company intends to initiate.

 

(f)          No
Conflict.  The execution, delivery and performance of this Agreement, the Note, the Warrant, and the other agreements
entered into by the Company in connection with the Offering (the “Transaction Documents”) and the consummation
by the Company of the transactions contemplated hereby and thereby will not: (i) conflict with or result in a violation of any
provision of the charter or bylaws of the Company or (ii) violate or conflict with, or result in a breach of any provision of,
or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others
any rights of termination, amendment, acceleration or cancellation of, any material agreement, indenture, patent, patent license
or instrument to which the Company is a party, or (iii) to the knowledge of Company, result in a violation of any law, rule, regulation,
order, judgment or decree (including federal and state securities laws and regulations and regulations of any self-regulatory organizations
to which the Company or its securities are subject) (“Laws”) applicable to the Company or by which any property
or asset of the Company is bound or affected.  The Company is not in violation of its charter, bylaws, or other organizational
documents.  The business of the Company is not being conducted in violation of any Law of any governmental entity, except
for possible violations which would not, individually or in the aggregate, have a Material Adverse Effect.  Except for
filings pursuant to Regulation D of the Securities Act, and applicable state securities laws, which have been made or will
be made by the Company in the required time thereunder, the Company is not required to obtain any consent, authorization or order
of, or make any filing or registration with, any court, governmental agency, regulatory agency, self-regulatory organization or
stock market or any third party in order for it to execute, deliver or perform any of its obligations under this Agreement or any
Transaction Document in accordance with the terms hereof or thereof or to issue and sell the Securities in accordance with the
terms hereof.

 

(g)          Intellectual
Property.  Other than inventions of the Company whose patent applications have yet to be filed, Schedule 3(g)
to this Agreement sets forth a complete and accurate listing of all of the Company’s patents and patent applications (“Patents”).
Except as set forth on Schedule 3(g) or as otherwise described in the PPM, to the best of Company’s knowledge, the
Company owns valid title, free and clear of any Liens, or possesses the requisite valid and current licenses or rights, free and
clear of any Liens, to use the Patents, copyrights, trademarks, service marks, trade names, Internet domain names, technology,
know-how (including trade secrets and other unpatented and/or unpatentable proprietary rights) and other intellectual property
in connection with the conduct of its business as now operated as presently contemplated to be operated in the future (collectively,
the “Intellectual Property”). Other than as set forth on Schedule 3(g) to this Agreement, to the knowledge
of Company, none of the Intellectual Property is unenforceable or invalid; none of the Company has received any notice of violation
or conflict with (and none of the Company knows of any basis for violation or conflict with) rights of others with respect to the
Intellectual Property; there are no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim
by others that allege the Company is infringing any patent, trade secret, trademark, service mark, copyright or other intellectual
property or proprietary right. To the knowledge of Company (i) the Company’s current and intended products, services and
processes do not violate or conflict with any intellectual property or proprietary right of any third party; and (ii) no officer,
director or employee of the Company is in or has ever been in violation of any term of any patent non-disclosure agreement, invention
assignment agreement, or similar agreement relating to the protection, ownership, development use or transfer of the Intellectual
Property or any other intellectual property. The Company is not in breach of, and has complied in all material respects with all
terms of, any license or other agreement relating to the Intellectual Property. The Company has taken reasonable steps to protect
and preserve the confidentiality of applicable Intellectual Property (“Confidential Information”). To the knowledge
of Company, all use or disclosure of Confidential Information not owned by the Company has been pursuant to the terms of a written
agreement between the Company and the owner of such Confidential Information, or is otherwise lawful. 

 

    	 	5	 

     

    

 

(h)          Patents.
The pending patent applications set forth in Schedule 3(g) (the “Pending Patents”) are being diligently
prosecuted by the Company and/or Subsidiaries. To the Company’s knowledge, there is no existing patent or published patent
application that would interfere, conflict with or otherwise adversely affect the validity, enforcement or scope of the Pending
Patents if claims of such Pending Patents were issued in substantially the same form as currently written. Except as set forth
on Schedule 3(g), (i) no security interests or other Liens have been created with respect to the Pending Patents; and (ii)
the Pending Patents have not been exclusively licensed to another entity or Person. 

 

(i)          Insurance.
The Company and each Subsidiary maintain insurance covering their respective properties as the Company reasonably deems adequate
and as is customary for companies engaged in similar businesses. Such insurance protects the Company and the Subsidiaries against
losses and risks to an extent which is necessary and reasonably adequate to protect the Company and each Subsidiary and their respective
businesses and includes, but is not limited to, reasonable directors’ and officers’ insurance coverage. None of the
Company nor any Subsidiary has reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business. There is
no material insurance claim made by or against the Company or any Subsidiary pending, outstanding, or, to the knowledge of the
Company, threatened, and, to the knowledge of the Company, no facts or circumstances exist which would reasonably be expected to
give rise to any such claim, and all due premiums in respective thereof have been paid.

 

(j)          SEC
Reports. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company
under the Securities Act and the Exchange Act of 1934, as amended (the “Exchange Act”), including pursuant to
Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required
by Law to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference
therein being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid
extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange
Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading.

 

(k)          Termination
of Contracts. None of the Company or any Subsidiary has sent or received any communications regarding termination of, or intent
not to renew, any Material Agreement (as defined below) or any of the contracts or agreements referred to or described in the Private
Placement Memorandum incident to this Offering (the “PPM”), and no such termination or non-renewal has been
threatened by the Company or any Subsidiary or, to the knowledge of the Company, any other party to such contract or agreement.

 

(l)          Management.  As
of the date of this Agreement, the Company’s Board of Directors and named executive officers consists of the individuals
identified in the SEC Reports. 

 

(m)          Financial
Statements.  The Financial Statements included in the SEC Reports fairly present the financial condition and operating
results of the Company as of the dates, and for the periods, indicated therein, subject to normal year-end audit adjustments.  Said
financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”)
applied on a consistent basis throughout the periods involved. Except as set forth in the Financial Statements, the Company has
no material liabilities or obligations, contingent or otherwise, other than liabilities incurred in connection with the consummation
of the transactions contemplated under the Offering, as described in the PPM, and those incurred in the ordinary course of business
subsequent to June 30, 2016.  Since June 30, 2016, nothing has occurred which would have a Material Adverse Effect.

 

(n)          Financial
Information and Projections.  Any financial estimates and projections in the PPM have been prepared by
management of the Company and are the most current financial estimates and projections available by the
Company.  Although the Company does not warrant that the results contained in such projections will be achieved, to
the best of the Company’s knowledge and belief, such projections are reasonable estimations of future financial
performance of the Company and its expected financial position, results of operations, and cash flows for the projection
period (subject to the uncertainty and approximation inherent in any projection).  At the time they were made, all
of the material assumptions upon which the projections are based were, to the best of the Company’s knowledge and
belief, reasonable and appropriate.  Nothing in this Section 3(n) is intended to modify or amend in any way
the representations and warranties of the Purchaser in Section 4.

 

    	 	6	 

     

    

 

(o)          Material
Changes; Undisclosed Events, Liabilities or Developments. None of the Company or its Subsidiaries has sustained, since the
date of the latest audited financial statements included in the PPM, any material loss or interference with its business from fire,
explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action,
order or decree. Since the respective dates as of which information is given in the PPM and except as disclosed herein or in the
PPM, (i) there has not been any change in the share capital of the Company or any Subsidiary and none of the Company or any Subsidiary
has declared any dividends or other distribution of cash or property to shareholders and none the Company nor any Subsidiary has
entered into any agreement to purchase, redeem or any other agreement with respect to its capital stock, including the issuance
of capital stock to the officers and directors of the Company and any Subsidiary; (ii) the Company has not incurred any liabilities
(contingent or otherwise) other than trade payables and accrued expenses incurred in the ordinary course of business consistent
with past practice; (iii) the Company has not altered its method of accounting; and (iv) there has not been any material adverse
change, or any development involving a prospective material adverse change, in or affecting the general affairs, management, financial
position, shareholders’ equity, results of operations or prospects of the Company and its Subsidiaries, taken as a whole
(a “Material Adverse Effect”). The Company does not have pending before the Securities and Exchange Commission
(the “Commission”) any request for confidential treatment of information. Except for the issuance of the Securities
contemplated by this Agreement and the transactions disclosed herein or in the PPM, no event, liability, fact, circumstance, occurrence
or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries
or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed
by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly
disclosed at least one trading day prior to the date that this representation is made.

 

(p)          Labor
Relations. There are no private, regulatory or governmental inquiry, action, suit, proceeding, litigation, claim, arbitration
or investigation pending before any Governmental Authority (as defined below) of competent jurisdiction (each, an “Action”)
pending or, to the knowledge of the Company, threatened involving the Company or any Subsidiary and any of their respective employees
or former employees (with respect to their status as an employee or former employee, as applicable) including any harassment, discrimination,
retaliatory act or similar claim. To the Company’s knowledge, since December 31, 2012, there has been: (i) no labor union
organizing or attempting to organize any employee of the Company or any of its Subsidiaries into one or more collective bargaining
units with respect to their employment with the Company or any of its Subsidiaries; and (ii) no labor dispute, strike, work slowdown,
work stoppage or lock out or other collective labor action by or with respect to any employees of the Company or any of its Subsidiaries
pending with respect to their employment with the Company or any of its Subsidiaries or threatened against the Company or any of
its Subsidiaries. Neither the Company nor any of its Subsidiaries is a party to, or bound by, any collective bargaining agreement
or other agreement with any labor organization applicable to the employees of the Company or any of its Subsidiaries and no such
agreement is currently being negotiated. To the knowledge of the Company, the Company and its Subsidiaries (i) are in compliance
in all material respects with all applicable Laws respecting employment and employment practices, terms and conditions of employment,
health and safety and wages and hours, including Laws relating to discrimination, disability, labor relations, hours of work, payment
of wages and overtime wages, pay equity, immigration, workers compensation, working conditions, employee scheduling, occupational
safety and health, family and medical leave, and employee terminations, and have not received written notice, or any other form
of notice, that there is any Action involving unfair labor practices against the Company or any of its Subsidiaries pending, (ii)
are not liable for any material arrears of wages or any material penalty for failure to comply with any of the foregoing, and (iii)
are not liable for any material payment to any trust or to any Governmental Authority, with respect to unemployment compensation
benefits, Taxes, social security or other benefits or obligations for employees, independent contractors or consultants (other
than routine payments to be made in the ordinary course of business and consistent with past practice). Except as would not result
in any material liability to the Company or any Subsidiary, there are no Actions pending or, to the knowledge of the Company, threatened
against the Company or any Subsidiary brought by or on behalf of any applicant for employment, any current or former employee,
any Person alleging to be a current or former employee, or any Governmental Authority, relating to any such Law, or alleging breach
of any express or implied contract of employment, wrongful termination of employment, or alleging any other discriminatory, wrongful
or tortious conduct in connection with the employment relationship.

 

(q)          [Reserved]

 

(r)          Compliance.
None of the Company or any Subsidiary is (i) in material breach of or in default under any Laws of the United States, or any other
jurisdiction where it was incorporated or operates, (ii) in breach of or in default under any approval, consent, waiver, authorization,
exemption, permission, endorsement or license granted by any court or governmental agency or body or any stock exchange authorities
(each a “Governmental Authority”) in the United States or any other jurisdiction in which it was incorporated
or operates, (iii) in violation of its constituent documents or (iv) in default in the performance or observance of any obligation,
agreement, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement
or instrument to which it is a party or by which it or any of its properties may be bound except, with respect to (i), (ii) or
(iv), where any default would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

    	 	7	 

     

    

 

(s)          Licenses
and Permits. Except as set forth on Schedule 3(s), the Company and its Subsidiaries possess all certificates, authorizations,
consents, approvals, orders, licenses and permits issued by the appropriate federal, state, national and foreign regulatory authorities
(collectively, the “Material Permits”) and any other state, federal, national and foreign agencies or bodies
engaged in the regulation of waste management, the processing of “big data” or the “Internet of things”
that are necessary to conduct their respective businesses as they are currently being conducted and as they are proposed to be
conducted except where any failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. All of such Material Permits are valid and in full force and effect, except where the invalidity of such Permits
or the failure to be in full force and effect, individually or in the aggregate, would not have a Material Adverse Effect. There
is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or investigation that individually or in
the aggregate would reasonably be expected to lead to the revocation, modification, termination, suspension or any other impairment
of the rights of the holder of any such Material Permit which revocation, modification, termination, suspension or other impairment
would have a material adverse effect on the Company and its subsidiaries, taken as a whole. Such Material Permits contain no material
restrictions or conditions not described in the PPM. None of the Company or any Subsidiary has a reasonable basis to believe that
any regulatory body is considering modifying, suspending or revoking any such Material Permit and each of the Company and each
Subsidiary is in material compliance with the provisions of all such Material Permits.

 

(t)          Regulatory
Matters. Except as described in the PPM, the Company and each of its subsidiaries: (A) are and at all times have been in material
compliance with all statutes, rules and regulations applicable to the ownership, testing, development, manufacture, assembly, use,
distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product sold, under
development, manufactured or distributed by the Company or any subsidiary (“Applicable Regulatory Laws”); (B)
have not received any notice of adverse finding, warning letter, or other correspondence or written notice from any federal, state,
local, national or foreign governmental or regulatory authority alleging or asserting material noncompliance with any Applicable
Regulatory Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto
required by any such Applicable Regulatory Laws (“Authorizations”); (C) possess all material Authorizations
and such Authorizations are valid and in full force and effect and neither the Company nor any subsidiary is in material violation
of any term of any such Authorizations; (D) have not received written notice of any proceeding, hearing, enforcement, investigation,
arbitration or other action from any federal, state, local, national or foreign governmental or regulatory authority or third party
alleging that any product, operation or activity is in material violation of any Applicable Regulatory Laws or Authorizations and
has no knowledge that any federal, state, local, national or foreign governmental or regulatory authority or third party is considering
any such proceeding, hearing, enforcement, investigation, arbitration or other action; (E) have not received written notice that
any federal, state, local, national or foreign governmental or regulatory authority has taken, is taking or intends to take action
to limit, suspend, modify or revoke any material Authorizations and has no knowledge that any federal, state, local, national or
foreign governmental or regulatory authority is considering such action; and (F) have filed, obtained, maintained or submitted
all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by
any Applicable Regulatory Laws or Authorizations except where the failure to file such reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments would not result in a Material Adverse Effect, and that all such reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and
correct on the date filed (or were corrected or supplemented by a subsequent submission).

 

(u)          Tax
Matters.  The Company has made or filed all federal, state and foreign income and all other tax returns, reports
and declarations required by any jurisdiction to which it is subject and has paid all taxes and other governmental assessments
and charges, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith
and has set aside on its books provisions reasonably adequate for the payment of all taxes for periods subsequent to the periods
to which such returns, reports or declarations apply.  All such tax returns and reports filed on behalf of the Company
were complete and correct and were prepared in good faith without willful misrepresentation.  There are no unpaid taxes
in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no
basis for any such claim.  The Company has not executed a waiver with respect to the statute of limitations relating
to the assessment or collection of any foreign, federal, state or local tax. Except as disclosed on Schedule 3(u), the
Company has not received notice that any of its tax returns is presently being audited by any taxing authority.

 

(v)         Certain
Transactions.  Except as set forth on Schedule 3(v) to this Agreement, none of the officers or directors of
the Company or any Subsidiary and none of the employees or consultants of the Company or any Subsidiary (including his/her spouse,
infant children, any company or undertaking in which he/she holds a controlling interest) is presently a party to any transaction
with the Company or any Subsidiary (other than for services as employees, consultants, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property
to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer,
director or such employee, consultant or any entity in which any officer, director, or any such employee or consultant has a substantial
interest or is an officer, director, trustee, stockholder, member or partner other than for (i) payment of salary or consulting
fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits,
including stock option under any stock option plan of the Company. Except as set forth on Schedule 3(v), there are no material
relationships or transactions between the Company and/or a Subsidiary on the one hand and the Company’s affiliates, officers
and directors or their shareholders, customers or suppliers on the other hand which, although required to be disclosed, are not
disclosed in the PPM.

 

    	 	8	 

     

    

 

(w)          Material
Agreements.  Except as disclosed on Schedule 3(w) to this Agreement (each contract, agreement, commitment
or understanding disclosed on Schedule 3(w) being hereinafter referred to as a “Material Agreement”))
or as contemplated by this Agreement or any Transaction Document, there are no agreements, understandings, commitments, instruments,
contracts, employment agreements, proposed transactions or judgments to which the Company is a party or by which it is bound which
may involve obligations (contingent or otherwise), or a related series of obligations (contingent or otherwise), of or to, or payments,
or a related series of payments, by or to the Company in excess of $250,000 in any one year.  All Material Agreements
are in full force and effect and constitute legal, valid and binding obligations of the Company, and to the Company’s knowledge,
the other parties thereto, and are enforceable in accordance with their respective terms.  Neither the Company nor, to
the Company’s knowledge, any person is in default under the terms of any Material Agreement, and no circumstance exists that
would, with the giving of notice or the passage of time, constitute a default under any Material Agreement.

 

(x)          Title
to Assets.  The Company has good and marketable title to all real and personal property owned by it that is material
to the business of the Company, in each case free and clear of all liens and encumbrances, except those, if any, included on Schedule
3(x) or incurred in the ordinary course of business consistent with past practice.  Any real property and facilities
held under lease by the Company are held by it under valid, subsisting and enforceable leases (subject to laws of general application
relating to bankruptcy, insolvency, reorganization, or other similar laws affecting creditors’ rights generally and other
equitable remedies) with which the Company is in compliance in all material respects.

 

(y)          Subsidiaries;
Joint Ventures.  Except for the subsidiaries described in Schedule 3(a), the Company has no subsidiaries and
(i) does not otherwise own or control, directly or indirectly, any other Person and (ii) does not hold equity interests, directly
or indirectly, in any other Person. Except as otherwise disclosed herein or in the PPM, the Company is not a participant
in any joint venture, partnership, or similar arrangement material to its business.  

 

(z)          Sarbanes-Oxley;
Internal Accounting Controls. The Company and the Subsidiaries are in material compliance with any and all applicable requirements
of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated
by the Commission thereunder that are effective as of the date hereof and as of the applicable Closing Date. As disclosed in the
SEC Reports, the Company and the Subsidiaries do not maintain a system of internal accounting controls sufficient to provide reasonable
assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. The disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
for the Company and the Subsidiaries are not effective to ensure that information required to be disclosed by the Company in the
reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified
in the Commission’s rules and forms. The Company’s certifying officers have evaluated the effectiveness of the disclosure
controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic
report under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently
filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes
in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries
that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the
Company and its Subsidiaries. Neither the Company’s Board of Directors nor its internal auditors have recommended that the
Company review or investigate, (i) adding to, deleting, changing the application of, or changing the Company’s disclosure
with respect to, any of the Company’s material accounting policies; (ii) any matter which could result in a restatement of
the Company’s financial statements for any annual or interim period during the current or prior three fiscal years; or (iii)
any significant deficiency, material weakness, change in internal controls or fraud involving management or other employees who
have a significant role in internal controls.

 

    	 	9	 

     

    

 

(aa)         Disclosure.
The Company understands and confirms that the Purchaser will rely on the representations and warranties contained herein in effecting
transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchaser regarding
the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the PPM and the
disclosure schedules to this Agreement, taken as a whole, is true and correct and does not contain any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under
which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date
of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were
made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties
with respect to the transactions contemplated hereby other than those specifically set forth in Section 4 hereof.

 

(bb)         Solvency.
Based on the consolidated financial condition of the Company as of the applicable Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Securities hereunder representing the Minimum Amount, the fair saleable value
of the Company’s assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing
debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company’s assets do not constitute
unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs
taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital
requirements and capital availability thereof and (iii) the current cash flow of the Company, together with the proceeds the Company
would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to
incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable
on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will
file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the
applicable Closing Date. Schedule 3(bb) sets forth as of the date hereof all outstanding secured and unsecured Indebtedness
of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement,
“Indebtedness” means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade
accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations
in respect of indebtedness of others, whether or not the same are or should be reflected in the Company’s consolidated balance
sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions
in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required
to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.

 

(cc)         Environmental.
The Company and each Subsidiary and their respective properties, assets and operations are in compliance in all material respects
with and hold all permits, authorizations and approvals required under Environmental Laws (as defined below). There are no past,
present or reasonably anticipated future events, conditions, circumstances, activities, practices, actions, omissions or plans
that could reasonably be expected to give rise to any material costs or liabilities to the Company or any Subsidiary under, or
to interfere with or prevent compliance by any of the Company or a Subsidiary with, Environmental Laws. None of the Company or
any Subsidiary (i) is the subject of any investigation, (ii) has received any notice or claim, (iii) is a party to or affected
by any pending or threatened action, suit, investigation or proceeding, (iv) is bound by any judgment, decree or order or (v) has
entered into any agreement, in each case relating to any alleged violation of any Environmental Law or any actual or alleged release
or threatened release or cleanup at any location of any Hazardous Materials (as defined below), except where (i), (ii), (iii) and
(iv) would not, individually or in the aggregate, have a Material Adverse Effect. As used herein, “Environmental Law”
means any national, provincial, municipal or other local or foreign law, statute, ordinance, rule, regulation, order, notice, directive,
decree, judgment, injunction, permit, license, authorization or other binding requirement, or common law, relating to health, safety
or the protection, cleanup or restoration of the environment or natural resources, including those relating to the distribution,
processing, generation, treatment, storage, disposal, transportation, other handling or release or threatened release of Hazardous
Materials, and “Hazardous Materials” means any material (including, without limitation, pollutants, contaminants,
hazardous or toxic substances or wastes) that is regulated by or may give rise to liability under any Environmental Law.

 

(dd)         Fundamental
Transaction. None of the Company nor any Subsidiary is currently a party to any memorandum of understanding, letter of intent,
definitive agreement or any similar agreements with respect to a merger or consolidation or a material acquisition or disposition
of assets, technologies, business units or businesses.

 

(ee)         Forward-Looking
Statements. Each “forward-looking statement” (within the meaning of Section 27A of the Securities Act or Section
21E of the Exchange Act) contained in the SEC Reports and the PPM has been made or reaffirmed with a reasonable basis and in good
faith.

 

(ff)         Office
of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director, officer,
agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office
of Foreign Assets Control of the U.S. Treasury Department.

 

    	 	10	 

     

    

 

(gg)         U.S.
Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation within the
meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser’s
request.

 

(hh)         Bank
Holding Company Act. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act
of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the
“Federal Reserve”). Neither the Company nor any of its Subsidiaries or affiliates owns or controls, directly
or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or
more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

 

(ii)         Money
Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money
Laundering Laws”), and no action, suit, investigation or proceeding by or before any court or governmental agency, authority
or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the
knowledge of the Company or any Subsidiary, threatened.

 

(jj)         Investment
Company. The Company is not, and is not an affiliate of, and immediately after receipt of payment for the Securities, will
not be or be an affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as
amended. The Company shall conduct its business in a manner so that it will not become an “investment company” subject
to registration under the Investment Company Act of 1940, as amended.

 

(kk)         Registration
Rights. Except as set forth on Schedule 3(kk), there are no contracts, agreements or understandings between the Company
and any Person granting such Person the right to require the Company to file a registration statement under the Securities Act
with respect to any securities of the Company owned or to be owned by such Person or to require the Company to include such securities
in the securities registered pursuant to a registration statement or in any securities being registered pursuant to any other registration
statement filed by the Company under the Securities Act.

 

(ll)         No
General Solicitation. Neither the Company nor any person participating on the Company’s behalf in the transactions contemplated
hereby has conducted any “general solicitation,” as such term is defined in Regulation D promulgated under the Securities
Act, with respect to any securities offered in the Offering.

 

(mm)         No
Integrated Offering.  Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf,
has directly or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances
that would require registration under the Securities Act of the issuance of the Securities.  The issuance of the Securities
will not be integrated (as defined in Rule 502 of the Securities Act) with any other issuance of the Company’s securities
(past, current or future) that would require registration under the Securities Act of the issuance of the Securities.  

 

(nn)         Offering.  Subject
to the accuracy of the Purchaser’s representations and warranties in Section 4 of this Agreement, and the accuracy
of the other Purchasers’ representations and warranties in their respective Securities Purchase Agreements, the offer, sale
and issuance of the Securities in the Offering constitute transactions exempt from the registration requirements of Section 5 of
the Securities Act and from the registration or qualification requirements of applicable state securities laws, and neither the
Company nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemption.

 

(oo)           Risks
Related to the Company and the Offering.  An investment in the Securities involves a high degree of risk and uncertainty.  The
PPM includes information about the material risks faced by the Company, however, they may not be the only risks.  Additional
unknown risks or risks that the Company currently considers to be immaterial may also impair the Company’s business operations.  If
any of the events or circumstances described in the PPM actually occurs, the Company’s business, financial condition or results
of operations could suffer.

 

4.             Purchaser
Acknowledgements and Representations.  In connection with the purchase of the Securities, Purchaser represents and
warrants as of the Closing Date applicable to the Purchaser and/or acknowledges, to the Company, the following:

 

(a)          Acceptance.  The
Company may accept or reject this Agreement and the number of Securities subscribed for hereunder, in whole or in part, in its
sole and absolute discretion.  The Company has no obligation to issue any of the Securities to any person who is a resident
of a jurisdiction in which the issuance of the Securities would constitute a violation of federal or state securities laws.

 

    	 	11	 

     

    

 

(b)          Irrevocability.  This
Agreement is and shall be irrevocable, except that the Purchaser shall have no obligations hereunder to the extent that this Agreement
is rejected by the Company.

 

(c)          Binding.  This
Agreement and the rights, powers and duties set forth herein shall be binding upon the Purchaser, the Purchaser’s heirs,
estate, legal representatives, successors and assigns and shall inure to the benefit of the Company, its successors and assigns.

 

(d)          No
Governmental Review.  No federal or state agency has made any finding or determination as to the fairness of the
Offering for investment, or any recommendation or endorsement of the Securities.

 

(e)          No
Voting Rights.  Unless and until the Warrant is exercised or the Note is converted and the Common Stock issued, the
Purchaser is not entitled to voting rights for the shares of Common Stock underlying the Notes and Warrants.  

 

(f)          Professional
Advice; Investment Experience.  The Company has made available to the Purchaser, or to the Purchaser’s attorney,
accountant or representative, all documents that the Purchaser has requested, and the Purchaser has requested all documents and
other information that the Purchaser has deemed necessary to consider respecting an investment in the Company.  The Company
has provided answers to all questions concerning the Offering and an investment in the Company.  The Purchaser has carefully
considered and has, to the extent the Purchaser believes necessary, discussed with the Purchaser’s professional technical,
legal, tax and financial advisers and his/her/its representative (if any) the suitability of an investment in the Company for the
Purchaser’s particular tax and financial situation.  All information the Purchaser has provided to the Company
concerning the Purchaser and the Purchaser’s financial position is, to Purchaser’s knowledge, correct and complete
as of the date set forth below, and if there should be any material adverse change in such information prior to the acceptance
of this Agreement by the Company, the Purchaser will immediately provide such information to the Company.  The Purchaser
has such knowledge, skill, and experience in technical, business, financial, and investment matters so that he/she/it is capable
of evaluating the merits and risks of an investment in the Securities.  To the extent necessary, the Purchaser has retained,
at his/her/its own expense, and relied upon, appropriate professional advice regarding the technical, investment, tax, and legal
merits and consequences of this Agreement and owning the Securities.  The Purchaser acknowledges and understands that
the proceeds from the sale of the Securities will be used as described in Section 5(c).

 

(g)          Investment
Purpose.  Purchaser is purchasing the Securities for investment for his, her or its own account only and not with
a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act in
violation of such act.  Purchaser further represents that he/she/it does not presently have any contract, undertaking,
agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with
respect to any of the Securities.  If the Purchaser is an entity, the Purchaser represents that it has not been formed
for the specific purpose of acquiring the Securities.  Purchaser acknowledges that an investment in the Securities is
a high-risk, speculative investment.

 

 (h)          Reliance
on Exemptions.  Purchaser understands that the Securities are being offered and sold to it in reliance upon specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying
upon the truth and accuracy of, and the Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of Purchaser set forth herein and in Exhibit A or Exhibit B, as applicable, in order to determine
the availability of such exemptions and the eligibility of the Purchaser to acquire the Securities.

 

(i)          Restricted
Securities.  Purchaser understands that the Securities are “restricted securities” under applicable Securities
Laws and that, pursuant to these laws, Purchaser must hold the Securities indefinitely unless they are registered with the Commission
and qualified by state authorities, or an exemption from such registration and qualification requirements is available.  Purchaser
acknowledges that the Company has no obligation to register or qualify the Securities or Common Stock underlying the Securities
for resale.  

 

(j)          Professional
Advice.  The Company has not received from its legal counsel, accountants or professional advisors any independent
valuation of the Company or any of its equity securities, or any opinion as to the fairness of the terms of the Offering or the
adequacy of disclosure of materials pertaining to the Company or the Offering.

 

    	 	12	 

     

    

 

(k)          Risk
of Loss.  The Purchaser has adequate net worth and means of providing for his/her/its current needs and personal
contingencies to sustain a complete loss of the investment in the Securities at the time of investment, and the Purchaser has no
need for liquidity in the investment in the Securities.  The Purchaser understands that an investment in the Securities
is highly risky and that he/she/it could suffer a complete loss of his/her/its investment.

 

(l)          Information.  The
Purchaser understands that any plans, estimates and projections, provided by or on behalf of the Company, involve significant elements
of subjective judgment and analysis that may or may not be correct; that there can be no assurance that such plans, projections
or goals will be attained; and that any such plans, projections and estimates should not be relied upon as a promise of the future
performance of the Company.  The Purchaser acknowledges that neither the Company nor anyone acting on the Company’s
behalf makes any warranty, express or implied, as to the accuracy or correctness of any such plans, estimates and projections,
and there are no assurances that such plans, estimates and projections will be achieved.  The Purchaser understands that
the Company’s technology and products are new, and not all of the technology and/or products may be tested and commercialized,
and that there is no guarantee that the technology and products will be commercially successful.  The Purchaser understands
that all of the risks associated with the technology are not now known.  Before investing in the Offering, the Purchaser
has been given the opportunity to ask questions of the Company about the technology and the Company’s business and the Purchaser
has received answers to those questions.

 

(m)          Authorization;
Enforcement.  Each Transaction Document to which a Purchaser is a party: (i) has been duly and validly authorized,
(ii) has been duly executed and delivered on behalf of the Purchaser, and (iii) will constitute, upon execution and delivery by
the Purchaser thereof and the Company, the valid and binding agreements of the Purchaser enforceable in accordance with their terms,
except to the extent limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application
affecting enforcement of creditors’ rights and general principles of equity that restrict the availability of equitable or
legal remedies.

 

(n)          Residency.  If
the Purchaser is an individual, then Purchaser resides in the state or province identified in the address of such Purchaser set
forth in the Purchaser Questionnaire; if the Purchaser is a partnership, corporation, limited liability company or other entity,
then the office or offices of the Purchaser in which its principal place of business is identified in the address or addresses
of the Purchaser set forth in the Purchaser Questionnaire.

 

(o)          Communication
of Offer. The Purchaser was contacted by the Company with respect to a potential investment in the Securities.  The
Purchaser is not purchasing the Securities as a result of any “general solicitation” or “general advertising,”
as such terms are defined in Regulation D of the Securities Act, which includes, but is not limited to, any advertisement, article,
notice or other communication regarding the Securities published in any newspaper, magazine or similar media or on the internet
or broadcast over television, radio or the internet or presented at any seminar or any other general solicitation or general advertisement.

 

(p)          No
Conflicts.  The execution, delivery and performance by the Purchaser of this Agreement and the consummation by the
Purchaser of the transactions contemplated hereby will not (i) result in a violation of the organizational documents of the
Purchaser (if the Purchaser is an entity), (ii) conflict with, or constitute a default (or an event which with notice or lapse
of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which the Purchaser is a party, or (iii) result in a violation of any law, rule,
regulation, order, judgment or decree (including federal and state securities laws) applicable to the Purchaser.

 

(q)          Organization.  If
the Purchaser is an entity, it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its
organization with the requisite corporate or partnership power and authority to enter into and to consummate the transactions contemplated
by the applicable Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.  If the
Purchaser is an entity, the execution, delivery and performance by the Purchaser of the transactions contemplated by this Agreement
have been duly authorized by all necessary corporate or, if the Purchaser is not a corporation, such partnership, limited liability
company or other applicable like action, on the part of the Purchaser.

 

(r)          PPM.
The Purchaser has received a copy of the PPM, has had an opportunity to review and evaluate the disclosure in the PPM, and does
not have any questions or requests for additional information.

 

(s)          No
Other Representations.  Other than the representations and warranties contained in the Transaction Documents, the
Purchaser has not received and is not relying on any representation, warranties or assurances as to the Company, its business or
its prospects from the Company or any other person or entity.

 

    	 	13	 

     

    

 

5.             Covenants.

 

(a)           As
long as a Note is outstanding, without the written consent of the holders of an aggregate majority of the principal amount of the
Notes then outstanding, the Company will not, and will not permit any of its Subsidiaries to, directly or indirectly, undertake
the following:

 

(i)          increase
or decrease the authorized number of shares of the Company’s capital stock, except in connection with a reverse stock split
required for the Listing or as is required to ensure that the Company has reserved a sufficient number of shares of Common Stock
to issue upon conversion of the Notes and exercise of the Warrants;

 

(ii)         take
any action that results in the distribution of a dividend or the repurchase or redemption of any shares of capital stock (other
than pursuant to equity incentive agreements with service providers giving the Company the right to repurchase shares at the lower
of cost or fair market value upon the termination of services);

 

(iii)        amend
any provision of the Company’s Certificate of Incorporation or bylaws, except in order to increase or decrease the Company’s
capital stock as permitted in Section 5(a)(i) above;

 

(iv)        except
as otherwise disclosed on a Schedule hereto, take any action that results in a security interest being placed on all or substantially
all of the Company’s assets or Intellectual Property;

 

(v)         enter
into any material new line of business or material change to the Company’s existing line of business, which existing business
is understood to cover environmental technologies, as well as data measurement, collection and presentation from industrial equipment;

 

(vi)        replace
the Company’s Chief Executive Officer or other senior executive officers, except in the event of their respective death,
disability, incapacity or retirement;

 

(vii)       sell,
transfer, pledge, dispose of, license or enter into any exclusive distribution or exclusive partnership agreement related to any
of the Intellectual Property rights of the Company or other Company assets, other than in the ordinary course of business (it being
understood that entering into exclusive sub-distribution agreements in the nature of those disclosed in the PPM are in the ordinary
course of business);

 

(viii)      acquire
any business (whether by stock or asset purchase, merger, consolidation or otherwise) in excess of $2,500,000 in aggregate purchase
price;

 

(ix)         enter
into an agreement to issue, or issue, any debt, equity or other securities of the Company that is pari passu or senior to the Notes,
or modify to the same effect any of the foregoing which may be outstanding (unless any such modification is no less favorable to
the Company than those currently outstanding), except for customary trade financing, mortgages, leases, or other commercial financing
activities or any stock option or incentive compensation plans;

 

(x)          engage
in any transactions with affiliates (for purposes of this subparagraph (xv), the term “affiliates” refers to the officers,
directors and holders of 10% or more of the Company’s common stock) except in connection with the Company’s lease from
BioHitech Realty LLC;

 

(xi)         liquidate,
enter into bankruptcy, dissolve or wind-up its business and affairs; or

 

(xii)        enter
into any Equity Line of Credit or similar agreement, or any issuance or agreement to issue any floating or Variable Rate Securities
(as defined below) or any of the foregoing or equity with price reset rights. For purposes hereof, “Equity Line of Credit”
shall include any transaction involving a written agreement between the Company and an investor or underwriter whereby the Company
has the right to “put” its securities to the investor or underwriter over an agreed period of time and at an agreed
price or price formula, and “Variable Rate Securities” shall include: (A) any debt or equity securities which are convertible
into, exercisable or exchangeable for, or carry the right to receive additional shares of Common Stock or with a fixed conversion,
exercise or exchange price that is subject to being reset at some future date at any time after the initial issuance of such debt
or equity security, and (B) any amortizing convertible security which amortizes prior to its maturity date, where the Company is
required or has the option to (or any investor in such transaction has the option to require the Company to) make such amortization
payments in shares of Common Stock.

 

    	 	14	 

     

    

 

(b)          Until
the later of (i) the repayment of the Notes in full and (ii) the exercise of all Warrants on or prior to their expiration, the
Company covenants to maintain the registration of its Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely
file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by
the Company after the date hereof pursuant to Section 13 or 15(d) the Exchange Act with the Commission even if the Company is not
then subject to the reporting requirements of Section 13 or 15(d) the Exchange Act. If at any time Rule 144 (as defined below)
is not available with respect to the Shares or the shares of Common Stock underlying the Warrants or Notes due to the Company’s
failure to remain current with its reporting obligations under the Exchange Act (“Public Information Failure”),
then the Company shall pay in cash by wire transfer of immediately available funds an amount per month equal to 1% of the aggregate
VWAP of all of the Shares or shares of Common Stock underlying the Warrants or Notes which are not able to be delivered to the
holder thereof without legend because of such Public Information Failure. Such Public Information Failure payments shall continue
until such time as the Shares or shares of Common Stock underlying the Warrants or Notes, as the case may be, are able to be delivered
without legend (to be pro-rated for any periods which are less than one month). As used herein, “Rule 144” means
Rule 144 promulgated by the Commission under the Securities Act, as such rule may be amended from time to time, or any other similar
or successor rule or regulation of the Commission that may at any time permit the Purchasers to sell securities of the Company
to the public without registration, and “VWAP” means, for any date, the price determined by the first of the
following clauses that applies: (a) the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on The Nasdaq Stock Market or NYSE MKT, (b) if the Common Stock is not then listed or quoted for trading on The Nasdaq Stock
Market or NYSE MKT, the OTCQB or such other quotation system or association, (c) and if prices for the Common Stock are not then
reported in or by any of the foregoing, in the “Pink Sheets” published by Pink OTC Markets, Inc. (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.

 

(c)          The
Company covenants and agrees that it will use the net proceeds from the Offering as set forth in the PPM.

 

(d)          The
shares of Common Stock or securities convertible into or exercisable for shares of Common Stock which are held by any of the Company’s
officers and directors and employees of the Company who own more than 1% of the outstanding and issued shares of the Company will
be locked up until 6 months following the Final Closing Date.

 

6.             Restrictive
Legends and Stop-Transfer Orders.

 

(a)           Legends.  The
certificate or certificates representing each of the Securities shall bear a legend substantially to the following effect (as well
as any legends required by applicable state corporate law or federal or state securities laws):

 

		(i)	THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE.  THEY MAY NOT BE
SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT
WITH RESPECT TO SUCH SECURITIES UNDER SUCH ACT AND/OR QUALIFICATION UNDER APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION AND QUALIFICATION IS NOT REQUIRED.

 

		(ii)	THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY
IN ACCORDANCE WITH THE TERMS OF THAT CERTAIN SECURITIES PURCHASE AGREEMENT BETWEEN THE COMPANY AND THE SECURITY HOLDER DATED ______________,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.

 

		(iii)	Any legend required to be placed thereon by any appropriate
securities commission or commissioner.

 

(b)          Stop-Transfer
Notices.  The Purchaser agrees that, to ensure compliance with the restrictions referred to herein, the Company may
issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its
own securities, it may make appropriate notations to the same effect in its own records.

 

(c)          The
Company, shall pay, on behalf of any Purchaser requesting the transfer or resale of Securities pursuant to Section 6(a)(i), a sum
sufficient to reimburse any expenses or fees that may be reasonably imposed in connection with the processing of such transfer,
provided that such expenses or fees relate to transfer agent charges, the cost of issuing new certificates or an opinion of counsel
relating to the lifting of the transfer legends.

 

    	 	15	 

     

    

 

(d)          The
Shares and shares of Common Stock underlying the Warrants and Notes shall be further subject to a customary lockup agreement in
the event that the Shares and/or shares of Common Stock underlying the Warrants and Notes become freely tradable under Rule 144
prior to a Listing or Public Offering.

  

7.             Conditions
to Closing.

 

(a)          Conditions
to the Company’s Obligation to Sell.  The obligation of the Company hereunder to issue and sell Securities
to the Purchaser is subject to the satisfaction, at or before the applicable Closing Date, of each of the following conditions,
provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole
discretion:

 

(i)          The
Purchaser shall have complied with Sections 2(a) and (b);

 

(ii)         The
representations and warranties of the Purchaser shall be true and correct in all material respects; and

 

(iii)        No
litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority
over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

(b)          Conditions
to Each Purchaser’s Obligation to Purchase.  The obligation of the Purchaser hereunder to purchase the Securities
is subject to the satisfaction, at or before the applicable Closing Date of each of the following conditions, provided that these
conditions are for the Purchaser’s sole benefit and may be waived by the Purchaser at any time in his/her/its sole discretion:

 

(i)          The
Company shall have complied with Section 2(d) in all material respects;

 

(ii)         The
representations and warranties of the Company shall be true and correct as of the applicable Closing Date, and the Company shall
have performed, satisfied and complied with the covenants, agreements and conditions required by this Agreement to be performed,
satisfied or complied with by the Company at or prior to the applicable Closing Date;

 

(iii)        No
litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority
over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement;
and

 

(iv)        No
event shall have occurred which would reasonably be expected to have a Material Adverse Effect on the Company.

 

8.             Miscellaneous.

 

(a)          Governing
Law.  This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties
hereto shall be governed, construed and interpreted in accordance with the laws of the State of New York, without giving effect
to principles of conflicts of law.

 

(b)          Entire
Agreement; Enforcement of Rights.  This Agreement and the PPM, together with the exhibits and schedules attached
hereto, set forth the entire agreement and understanding of the parties relating to the subject matter herein and supersedes any
and all prior agreements or discussions between them, including any term sheet, letter of intent or other document executed by
the parties prior to the date hereof relating to such subject matter.  No modification of or amendment to this Agreement,
nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the parties to this Agreement.  The
failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.

 

    	 	16	 

     

    

 

(c)          Severability.  If
one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate
such provision in good faith.  If the parties cannot reach a mutually agreeable and enforceable replacement for such
provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of the Agreement shall be
interpreted as if such provision were so excluded, and (iii) the balance of the Agreement shall be enforceable in accordance
with its terms.

 

(d)          Construction.  This
Agreement is the result of negotiations between and has been reviewed by each of the parties hereto and their respective counsel,
if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed
in favor of or against any one of the parties hereto.

 

(e)          Notices.  Any
notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient when delivered personally (including
two business days after deposit with a reputable overnight courier service, properly addressed to the party to receive the same)
or sent by fax or 48 hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed
to the party to be notified at such party’s address or fax number as set forth herein or as subsequently modified by written
notice.

 

(f)          Counterparts.  This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall
constitute one instrument.

 

(g)          Successors
and Assigns.  The rights and benefits of this Agreement shall inure to the benefit of, and be enforceable by the
Company’s successors and assigns.  The covenants and obligations of the Company hereunder shall inure to the benefit
of, and be enforceable by the Purchaser against the Company, its successors and assigns, including any entity into which the Company
is merged.  The rights and obligations of Purchasers under this Agreement may only be assigned with the prior written
consent of the Company.

 

(h)          Third
Party Beneficiary.  This Agreement is intended for the benefit of the undersigned parties and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

(i)          Further
Assurances.  Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

(j)          Expenses.  The
Company and Purchaser shall each pay their respective costs and expenses incurred by them with respect to the negotiation, execution,
delivery and performance of this Agreement.

 

(k)          Survival.  The
representations, warranties, covenants and agreements made herein shall survive the closing of the transaction contemplated hereby.  All
statements as to factual matters contained in any certificate or other instrument delivered by or on behalf of the Company pursuant
hereto in connection with the transactions contemplated hereby shall be deemed to be representations and warranties by the Company
hereunder solely as of the date of such certificate or instrument.  The representations, warranties, covenants and obligations
of the Company, and the rights and remedies that may be exercised by the Purchaser, shall not be limited or otherwise affected
by or as a result of any information furnished to, or any investigation made by or knowledge of, any of the Purchasers or any of
their representatives.

 

(l)          Attorneys’
Fees.  In the event that any suit or action is instituted under or in relation to this Agreement, including without
limitation to enforce any provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the
losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement,
including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation,
all fees, costs and expenses of appeals.

 

 (m)         Remedies.  All
remedies afforded to any party by law or contract, shall be cumulative and not alternative and are in addition to all other rights
and remedies a party may have, including any right to equitable relief and any right to sue for damages as a result of a breach
of this Agreement.  Without limiting the foregoing, no exercise of a remedy shall be deemed an election excluding any
other remedy.

 

[Remainder of Page Intentionally Left
Blank] 

 

    	 	17	 

     

    

  

The Purchaser, by his, her or its signature below, or
by that of its authorized representative, confirms that the Purchaser has carefully reviewed and understands, and voluntarily enters
into, this Agreement.

 

IN WITNESS WHEREOF, the Purchaser has executed this Agreement
as of _______________, 201__.

 

	PURCHASER (if individual):	PURCHASER (if entity):
	 	 
	Signature	Name of Entity
	 	 
	Name (type or print)	By:
	 	 
	Signature of Co-Signer (if any)	Name:
	 	 
	Name of Co-Signer (type or print)	Its:

 

AGREED AND ACCEPTED as of ________________, 201__.

 

BIOHITECH GLOBAL, INC.

 

By: ___________________________________

 

Name: ________________________________

 

Title: __________________________________

 

Subscription Amount (as accepted by the Company):

 

$________________________

 

    	 	18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]